I-Mab Cash Flow Conversion Efficiency
I-Mab cash flow conversion efficiency. Based on the latest financial reports, I-Mab (IMAB) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.84 Million) by net assets ($258.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of I-Mab (2017–2024)
Cash flow conversion efficiency of I-Mab from 2017 to 2024. This chart illustrates how I-Mab's cash flow conversion efficiency has evolved over time, based on yearly financial data. View I-Mab stock price for real-time trading data and today's change.
I-Mab Cash Flow Conversion Ratio Explained
I-Mab cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
I-Mab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of I-Mab ranked by their cash flow conversion efficiency. Also see I-Mab stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHC Resources Corp
TW:9930
|
0.081x |
|
Zhejiang Tiantai Xianghe Industrial Co Ltd
SHG:603500
|
0.008x |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
-0.741x |
|
Sinopec Shandong Taishan Petroleum Co Ltd
SHE:000554
|
0.052x |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
0.002x |
|
Anshan Senyuan Road Bridge
SHE:300210
|
0.026x |
|
Bradespar S.A
SA:BRAP3
|
0.000x |
|
GENERAL Elevator Co. Ltd.
SHE:300931
|
0.001x |
Annual Cash Flow Conversion Efficiency for I-Mab (2017–2024)
The table below shows the annual cash flow conversion efficiency of I-Mab from 2017 to 2024. Review I-Mab free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.67 Million | -0.262x | +65.53% |
| 2023-12-31 | $1.72 Billion | $-1.30 Billion | -0.760x | -107.18% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more